Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is supported by a highly strategic acquisition by Tempus AI, which validates the company’s genomic sequencing and analytics platform and underscores the value of its NeXT Personal MRD franchise. Its fundamentals are improving, with Q1'26 molecular clinical test volume of 7,815 rising 258% year over year and 26% quarter over quarter, while Q1 Dx revenue of $1.4M exceeded expectations and 1,000+ oncologists are now ordering the test. The company also benefits from Medicare coverage, growing biopharma demand, and a 2Q26 revenue guide of $22.4M versus $16.8M consensus, suggesting expanding commercial traction and stronger visibility into future growth.

Bears say

Personalis is viewed negatively because its low gross margin and negative operating margin, combined with significant cash burn, suggest the business still lacks durable profitability even after Q1'26 revenue of $15.5M beat expectations. The outlook is further pressured by execution risk in clinical diagnostics, where Medicare or commercial payer coverage for the MRD test could fall short, while biopharma ordering patterns remain volatile and large pharma demand for personalized cancer vaccines could soften. In addition, the all-stock acquisition structure introduces closing risk because PSNL can terminate if TEM falls below $46.00 per share, and the current $48.25 level leaves only limited cushion.

Personalis Inc (PSNL) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 6 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.